I am very proud to announce that one of our Board of Directors’ mate from Boomerang, Alex Martin – CFO of Bioxell and Member of the Executive Committee, has organized the IPO on the Swiss Exchange (SWX: BXLN) of the company he is working for. BioXell is a biotech company based in Milano – Italy and is coming from a Roche spin-off in 2002. It is focusing on the discovery, development and commercialization of novel therapeutics for urological disorders and inflammatory diseases that represent large unmet medical needs. They have raised to date a total of approximately €76m through top healthcare VC investors including MPM Capital, Index Ventures, BB BIOTECH, AlpInvest Partners, Life Sciences Partners, and TVM Capital, as well as Finlombarda. About 60 people are working now for BioXell.

Some links to the news:

• Press Release from BioXell (pdf)
• BioWorld: Italy’s BioXell Goes Public On Swiss Market, Gets CHF57.8M
• Forbes: BioXell says new shares priced at 44 sfr/share, at bottom of price range
• AltAssets: BioXell lists on Swiss Stock Exchange

Congratulations Alex, great step :-)